Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for serious rare and ultra-rare genetic diseases. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on conditions that have high unmet medical need and limited or no approved treatment options. Its business model centers on developing biologics, gene therapies, and small-molecule products that can achieve meaningful clinical outcomes in narrowly defined patient populations.
Founded in 2010, Ultragenyx has evolved from a development-stage company into a commercial-stage enterprise with multiple approved products and a robust clinical pipeline. The company’s strategic positioning is built on deep expertise in rare disease biology, strong relationships with patient advocacy groups, and an integrated approach spanning research, clinical development, regulatory approval, and global commercialization.
Business Operations
Ultragenyx generates revenue primarily through the sale of its approved therapies, including Crysvita, Dojolvi, Mepsevii, and Evkeeza, which target distinct rare metabolic and genetic disorders. These products are marketed directly in major regions and through distribution and collaboration partners in certain international markets. Revenue is also influenced by milestone payments and collaborations related to development and commercialization partnerships.
The company operates across both domestic and international markets, with core capabilities in biologics manufacturing oversight, clinical development, regulatory affairs, and specialty commercial operations. Ultragenyx maintains a pipeline of clinical and preclinical programs, including gene therapy candidates developed through its internal research efforts and its wholly owned subsidiary GeneTx Biotherapeutics, which focuses on gene therapies for rare neurologic diseases.
Strategic Position & Investments
Ultragenyx’s strategy emphasizes expanding its portfolio through internal research, lifecycle management of approved products, and targeted acquisitions that strengthen its presence in rare and ultra-rare diseases. A key growth initiative includes advancing gene therapy programs and novel biologics aimed at addressing the underlying genetic causes of disease rather than symptomatic treatment.
Notable investments include the acquisition of GeneTx Biotherapeutics, which added multiple gene therapy programs to the company’s pipeline, and continued investment in late-stage clinical trials for both metabolic and neuromuscular disorders. The company is also involved in emerging technologies related to adeno-associated virus (AAV) gene delivery and antibody-based therapies, positioning it at the intersection of rare disease treatment and advanced therapeutic modalities.
Geographic Footprint
Ultragenyx is headquartered in the United States, with its principal offices located in California. The company has a significant commercial and operational presence in North America and Europe, supported by regional offices and specialized commercial teams focused on rare disease markets.
Beyond its core regions, Ultragenyx has expanded its reach into Latin America, the Middle East, and parts of Asia-Pacific through partnerships and distributors. This global footprint allows the company to address geographically dispersed patient populations and supports regulatory and market access efforts across multiple continents.
Leadership & Governance
Ultragenyx is led by a management team with extensive experience in rare diseases, biotechnology innovation, and global pharmaceutical commercialization. The leadership emphasizes a patient-centric philosophy, long-term scientific investment, and disciplined execution across development and commercial operations.
Key members of the executive leadership team include:
- Emil D. Kakkis – President and Chief Executive Officer
- Shalini Sharp – Chief Financial Officer
- Eric Crombez – Executive Vice President and Chief Medical Officer
- Howard Horn – Senior Vice President and General Counsel
- Fabiana Lopes Nunes – Executive Vice President and Chief Commercial Officer